For research use only. Not for therapeutic Use.
HPK1-IN-19 is a hematopoietic progenitor kinase 1 (HPK1) inhibitor extracted from patent WO2018102366A1 compound I-47[1].
Catalog Number | I045179 |
CAS Number | 2227609-33-6 |
Synonyms | 4-N-(2-dimethylphosphorylphenyl)-2-N-(6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)-5-(1-methylpyrazol-4-yl)pyrimidine-2,4-diamine |
Molecular Formula | C27H32N7O2P |
Purity | ≥95% |
InChI | InChI=1S/C27H32N7O2P/c1-33-11-10-18-13-24(36-3)23(12-19(18)16-33)31-27-28-15-21(20-14-29-34(2)17-20)26(32-27)30-22-8-6-7-9-25(22)37(4,5)35/h6-9,12-15,17H,10-11,16H2,1-5H3,(H2,28,30,31,32) |
InChIKey | AZENVIBXSMLBQC-UHFFFAOYSA-N |
SMILES | CN1CCC2=CC(=C(C=C2C1)NC3=NC=C(C(=N3)NC4=CC=CC=C4P(=O)(C)C)C5=CN(N=C5)C)OC |
Reference | [1]. Huang WS, et, al. Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors. WO2018102366A1. |